Literature DB >> 20630668

Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI.

Roberto Alonzi1, Anwar R Padhani, N Jane Taylor, David J Collins, James A D'Arcy, J James Stirling, Michele I Saunders, Peter J Hoskin.   

Abstract

PURPOSE: The antivascular effects of androgen deprivation have been investigated in animal models; however, there has been minimal investigation in human prostate cancer. This study tested the hypothesis that androgen deprivation causes significant reductions in human prostate tumor blood flow and the induction of hypoxia at a magnitude and in a time scale relevant to the neoadjuvant setting before radiotherapy. METHODS AND MATERIALS: Twenty patients were examined, each with five multi-parameter magnetic resonance imaging scans: two scans before the commencement of androgen suppression, one scan after 1 month of hormone treatment, and two further scans after 3 months of therapy. Quantitative parametric maps of the prostate informing on relative blood flow (rBF), relative blood volume (rBV), vascular permeability (transfer constant [K(trans)]), leakage space (v(e)) and blood oxygenation (intrinsic relaxivity [R(2)∗]) were calculated.
RESULTS: Tumor blood volume and blood flow decreased by 83% and 79%, respectively, in the first month (p < 0.0001), with 74% of patients showing significant changes. The proportion of individual patients who achieved significant changes in T1 kinetic parameter values after 3 months of androgen deprivation for tumor measurements was 68% for K(trans) and 53% for v(e) By 3 months, significant increases in R(2)∗ had occurred in prostate tumor, with a rise of 41.1% (p < 0.0001).
CONCLUSIONS: Androgen deprivation induces profound vascular collapse within 1 month of starting treatment. Increased R(2)∗ in regions of prostate cancer and a decrease in blood volume suggest a reduction in tumor oxygenation.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20630668     DOI: 10.1016/j.ijrobp.2010.02.060

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  24 in total

1.  Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer.

Authors:  Philip J Saylor; Kevin R Kozak; Matthew R Smith; Marek A Ancukiewicz; Jason A Efstathiou; Anthony L Zietman; Rakesh K Jain; Dan G Duda
Journal:  Oncologist       Date:  2012-02-02

Review 2.  Functional MRI and CT biomarkers in oncology.

Authors:  J M Winfield; G S Payne; N M deSouza
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-13       Impact factor: 9.236

3.  Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer.

Authors:  Kathrine Røe; Lars Tg Mikalsen; Albert J van der Kogel; Johan Bussink; Heidi Lyng; Anne H Ree; Laure Marignol; Dag R Olsen
Journal:  Radiat Oncol       Date:  2012-05-23       Impact factor: 3.481

4.  Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer clinical trials: potential roles and possible pitfalls.

Authors:  Fiona M Fennessy; Rana R McKay; Clair J Beard; Mary-Ellen Taplin; Clare M Tempany
Journal:  Transl Oncol       Date:  2014-02-01       Impact factor: 4.243

5.  Prostate Cancer: assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI.

Authors:  Andreas M Hötker; Yousef Mazaheri; Junting Zheng; Chaya S Moskowitz; Joshua Berkowitz; Joshua E Lantos; Xin Pei; Michael J Zelefsky; Hedvig Hricak; Oguz Akin
Journal:  Eur Radiol       Date:  2015-03-29       Impact factor: 5.315

Review 6.  Pharmacotherapeutic management of locally advanced prostate cancer: current status.

Authors:  Jarad M Martin; Stephane Supiot; Dominik R Berthold
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

Review 7.  Role of androgen and vitamin D receptors in endothelial cells from benign and malignant human prostate.

Authors:  Alejandro S Godoy; Ivy Chung; Viviana P Montecinos; Ralph Buttyan; Candace S Johnson; Gary J Smith
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-04-02       Impact factor: 4.310

8.  Near-simultaneous quantification of glucose uptake, mitochondrial membrane potential, and vascular parameters in murine flank tumors using quantitative diffuse reflectance and fluorescence spectroscopy.

Authors:  Caigang Zhu; Hannah L Martin; Brian T Crouch; Amy F Martinez; Martin Li; Gregory M Palmer; Mark W Dewhirst; Nimmi Ramanujam
Journal:  Biomed Opt Express       Date:  2018-06-27       Impact factor: 3.732

Review 9.  Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer.

Authors:  Tanya B Dorff; L Michael Glode
Journal:  Curr Opin Urol       Date:  2013-07       Impact factor: 2.309

10.  Using R2* values to evaluate brain tumours on magnetic resonance imaging: preliminary results.

Authors:  Zhenghua Liu; Haibo Liao; Jianhua Yin; Yanfang Li
Journal:  Eur Radiol       Date:  2013-11-26       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.